Executive Summary
The August 3, 2026 filings for the NASDAQ-100 stream reveal a stark divergence between AI-driven growth and legacy/asset-heavy business models. Palantir's exceptional 93% YoY revenue growth and raised guidance underscore the AI boom, while Strategy Inc's massive unrealized digital asset losses highlight the volatility of crypto-heavy balance sheets.
Insider activity is mixed, with a QUALCOMM HR executive selling and Intel insiders engaging in routine transactions. Capital allocation trends show aggressive ATM equity issuance by Strategy Inc to fund Bitcoin purchases and preferred dividends, while Gilead's 13F reveals a concentrated biotech investment portfolio. Sector themes point to AI monetization, crypto volatility, and insider activity patterns. Key catalysts include Palantir's Q3 earnings and continued Bitcoin price sensitivity for Strategy Inc.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 10-Q · 8-K · Form 4 · Schedule 13G · 13F
Tracking the trend? Catch up on the prior Nasdaq 100 Stocks SEC Filings digest from July 31, 2026.
Investment Signals (8)
- Palantir Technologies ↓ (BULLISH)▲
Total revenue surged 93% YoY to $1.935B, with U.S. commercial revenue up 149% YoY to $764M; full-year guidance raised to 82% YoY growth, crushing consensus
- Palantir Technologies ↓ (BULLISH)▲
Adjusted EBITDA margin of 62% ($1.202B) demonstrates exceptional profitability; GAAP EPS of $0.41 matches adjusted EPS, indicating high earnings quality
- Strategy Inc ↓ (BULLISH)▲
Subscription services revenue grew 54% YoY in Q2, showing strong software business momentum despite digital asset losses
- Strategy Inc ↓ (MIXED)▲
Total revenue grew 6.9% YoY in Q2 to $122.4M, but product support revenue declined 22.7% YoY, indicating a shift away from legacy products
- QUALCOMM ↓ (BEARISH)▲
EVP Ace Heather S sold 3,200 shares at $147.04 (~$471K) under a 10b5-1 plan; sale is small relative to holdings (36,535 shares remain), but insider selling at current levels warrants monitoring
- Intel ↓ (NEUTRAL)▲
Director Craig Barratt awarded 1,461 RSUs, aligning management with shareholders; EVP Chandrasekaran exercised 33,007 RSUs and had 14,738 shares withheld for taxes, indicating no open-market selling
- Gilead Sciences ↓ (BULLISH)▲
13F shows $1.65B concentrated in biotech holdings, with Arcus Biosciences ($968.8M) as the largest position, signaling strategic commitment to oncology partnerships
- Strategy Inc ↓ (MIXED)▲
Weekly ATM sales of 3.01M shares raised $290.6M, with $250M added to USD Reserve; Bitcoin holdings decreased by 1,638 BTC to 842,138 BTC, indicating active treasury management
Risk Flags (8)
- Strategy Inc/Financial↓ [HIGH RISK]▼
Net loss of $8.22B in Q2 2026 vs net income of $10.02B in Q2 2025, driven by $8.32B unrealized losses on digital assets; H1 loss of $20.76B vs $5.80B income
- Strategy Inc/Asset Value↓ [HIGH RISK]▼
Digital assets held decreased 15.6% from $58.85B to $49.67B in H1 2026, reflecting Bitcoin price declines and asset sales
- Strategy Inc/Revenue Mix↓ [MEDIUM RISK]▼
Product license revenue fell 48.9% YoY in Q2 and 36.5% in H1, indicating accelerating decline in legacy software sales
- Strategy Inc/Cash Flow↓ [MEDIUM RISK]▼
Weekly ATM sales of $290.6M and Bitcoin sales of 1,638 BTC to fund preferred dividends and repurchases suggest reliance on equity issuance for liquidity
- QUALCOMM/Insider Selling↓ [LOW RISK]▼
EVP Ace Heather S sold shares at $147.04, potentially signaling lack of confidence at current valuation; watch for further insider sales
- Lite Strategy/Investor Exit↓ [MEDIUM RISK]▼
Alexander Schornstein liquidated all shares, dropping beneficial ownership to 0.00%; complete exit by former major shareholder raises governance concerns
- Palantir/Concentration↓ [LOW RISK]▼
U.S. commercial revenue growing 149% YoY vs U.S. government at 90% YoY; reliance on commercial segment for growth may increase volatility
- Strategy Inc/Dividend Coverage↓ [MEDIUM RISK]▼
Preferred dividend rate maintained at 12.00% per annum, funded by Bitcoin sales; sustainability depends on Bitcoin price stability
Opportunities (6)
- Palantir/Growth↓ (OPPORTUNITY)◆
Q3 2026 revenue guidance of $2.160B-$2.164B implies continued momentum; adjusted operating income guidance of $1.292B-$1.296B suggests margin expansion
- Strategy Inc/Software Business↓ (OPPORTUNITY)◆
Subscription services up 54% YoY in Q2, indicating high-growth SaaS segment; potential spin-off or re-rating of software business
- Gilead/Partnerships↓ (OPPORTUNITY)◆
13F shows $968.8M in Arcus Biosciences, indicating deep partnership; upcoming clinical data readouts could drive upside
- Intel/Insider Alignment↓ (OPPORTUNITY)◆
Director RSU award and EVP RSU exercise signal confidence in turnaround; watch for foundry business milestones
- Strategy Inc/USD Reserve↓ (OPPORTUNITY)◆
$4.0B USD Reserve provides liquidity buffer; potential for opportunistic Bitcoin purchases at lower prices
- Palantir/Commercial Expansion↓ (OPPORTUNITY)◆
U.S. commercial revenue up 149% YoY, indicating successful enterprise AI adoption; continued growth expected
Sector Themes (5)
- AI Monetization◆
Palantir's 93% YoY revenue growth and 62% adjusted EBITDA margin demonstrate AI's profit potential, contrasting with Strategy Inc's legacy software decline [AI-driven growth is separating winners from losers]
- Crypto Volatility◆
Strategy Inc's $22.77B H1 unrealized losses highlight the risk of holding digital assets; Bitcoin price swings directly impact earnings [Crypto exposure creates earnings volatility]
- Insider Activity Patterns◆
Mixed insider signals: QUALCOMM selling, Intel RSU exercises, and Strategy Inc's ATM issuance suggest varied management conviction across sectors [Insider activity reflects sector-specific confidence]
- Capital Allocation Divergence◆
Strategy Inc uses ATM equity sales to fund Bitcoin purchases and dividends, while Palantir reinvests for growth; different strategies reflect business maturity [Capital allocation strategies vary by growth stage]
- Biotech Strategic Investments◆
Gilead's $1.65B in biotech holdings (Arcus, Assembly, Lakefront) shows large pharma using equity stakes to secure partnerships [Strategic investments in biotech are increasing]
Watch List (7)
-
Q3 2026 earnings (expected late October) to confirm guidance; watch for U.S. commercial growth sustainability [Earnings call]
-
Weekly ATM sales and Bitcoin holdings updates; monitor Bitcoin price for impact on net asset value and earnings [Weekly disclosures]
-
Further insider sales by executives; monitor 10b5-1 plan activity for additional selling [Insider activity]
- 👁
Foundry business updates and insider transactions; watch for RSU vesting and potential sales [Insider activity]
-
Clinical trial results for Arcus Biosciences (domuzart) and other pipeline assets; watch for partnership expansions [Clinical data]
-
Any strategic moves following Schornstein's exit; monitor for new investors or M&A activity [Corporate actions]
-
Preferred dividend coverage and STRC repurchase activity; watch for changes in dividend policy [Dividend sustainability]
Filing Analyses
(8)
03-08-2026
Strategy Inc reported a net loss of $8.22B for Q2 2026 and $20.76B for H1 2026, compared to net income of $10.02B and $5.80B in the same periods of 2025, driven by massive unrealized losses on digital assets ($8.32B in Q2, $22.77B in H1). Revenue grew 6.9% YoY in Q2 to $122.4M and 9.4% YoY in H1 to $246.7M, with subscription services up 54% in Q2 and 56% in H1. However, product support revenue declined 22.7% in Q2 and 19.3% in H1, and product license revenue fell 48.9% in Q2 and 36.5% in H1.
- · The company reported a net loss attributable to common stockholders of $8.62B for Q2 2026 and $21.39B for H1 2026, compared to net income of $9.97B and $5.75B in the prior year periods.
- · Unrealized loss on digital assets was $8.32B in Q2 2026 and $22.77B in H1 2026, versus unrealized gains of $14.05B and $8.14B in the same periods of 2025.
- · Digital assets held decreased 15.6% from $58.85B at Dec 31, 2025 to $49.67B at June 30, 2026.
- · The company purchased approximately 174,895 bitcoins in H1 2026 for $13.67B, and sold 1,395 bitcoins for $41.0M.
- · Long-term debt decreased 18.2% from $8.16B to $6.67B, partly due to $1.38B in convertible note repayments.
- · Mezzanine equity (Series A Perpetual Preferred Stock) more than doubled from $6.92B to $14.44B, reflecting $7.53B in preferred stock issuances.
- · Total stockholders' equity fell 30.0% from $44.12B to $30.89B, driven by the large net loss.
- · Cash and cash equivalents declined 25.6% from $2.30B to $1.71B, while total current assets increased slightly from $2.56B to $2.67B.
- · The company raised $8.25B from common stock offerings and $7.53B from preferred stock offerings in H1 2026.
- · Gross profit margin declined slightly: 66.6% in Q2 2026 vs 68.8% in Q2 2025, and 66.9% in H1 2026 vs 69.1% in H1 2025.
- · Operating expenses were dominated by the unrealized loss on digital assets; excluding that, operating expenses were $97.1M in Q2 2026 vs $94.3M in Q2 2025, and $195.4M in H1 2026 vs $186.8M in H1 2025.
- · The company had an accumulated deficit of $15.20B as of June 30, 2026, compared to retained earnings of $6.32B at Dec 31, 2025.
- · Weighted average diluted shares outstanding increased from 306,764 in Q2 2025 to 352,534 in Q2 2026, reflecting equity issuances.
03-08-2026
Palantir reported exceptional Q2 2026 results, with total revenue surging 93% YoY to $1.935B and U.S. commercial revenue skyrocketing 149% YoY to $764M. The company raised its full-year 2026 revenue guidance to 82% YoY growth and its U.S. commercial revenue guidance to at least 134% YoY growth, crushing consensus expectations. However, while all segments showed strong growth, U.S. government revenue grew at a slower 90% YoY compared to the 149% commercial growth, and the company's GAAP net income margin of 55% was slightly below its adjusted operating margin of 62%.
- · GAAP EPS (diluted) was $0.41, matching adjusted EPS (diluted) of $0.41.
- · Adjusted EBITDA was $1.202B, representing a 62% margin.
- · Q3 2026 revenue guidance is $2.160B-$2.164B; adjusted income from operations guidance is $1.292B-$1.296B.
- · FY 2026 adjusted free cash flow guidance raised to $4.5B-$4.7B.
- · The company expects GAAP operating income and net income in each quarter of 2026.
- · A live earnings webcast is scheduled for 5:00 PM ET on August 3, 2026.
03-08-2026
Director BARRATT CRAIG H was awarded 1,461 Restricted Stock Units.
- · Director BARRATT CRAIG H was awarded 1,461 Restricted Stock Units
03-08-2026
EVP, Chief HR Officer ACE HEATHER S sold 3,200 Common Stock at $147.04 (~$471K). ACE HEATHER S holds 36,535 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · EVP, Chief HR Officer ACE HEATHER S sold 3,200 Common Stock at $147.04 (~$471K)
03-08-2026
Alexander Schornstein filed a Schedule 13G/A with the SEC on August 3, 2026, reporting that he liquidated all of his shares in Lite Strategy, Inc. (formerly MEI Pharma, Inc.) as of June 30, 2026. As a result, he no longer holds any shares and his beneficial ownership has dropped to 0.00% of the company's 34,025,200 outstanding shares. This filing reflects a complete exit by a former major shareholder.
- · Alexander Schornstein's address is Kaiser-Friedrich-Allee 2, 52074 Aachen, Germany.
- · The company's common stock has a par value of $0.00000002 per share.
- · The company's fiscal year ends on June 30.
- · The outstanding share count is based on the company's Form 10-Q filed on May 13, 2026.
03-08-2026
Gilead Sciences, Inc. filed its quarterly 13F-HR report with the SEC for the period ending June 30, 2026, disclosing its equity holdings as of that date. The filing shows Gilead's investment portfolio includes positions in Arcus Biosciences, Assembly Biosciences, Lakefront Biotherapeutics, Kyverna Therapeutics, and Xilio Therapeutics, with a total reported value of approximately $1.65 billion across these five holdings.
- · Arcus Biosciences: 31,424,760 shares, value $968,825,351
- · Assembly Biosciences: 4,977,089 shares, value $136,770,406
- · Lakefront Biotherapeutics (SPON ADR): 16,707,477 shares, value $500,157,715
- · Kyverna Therapeutics: 4,126,119 shares, value $36,763,720
- · Xilio Therapeutics: 650,389 shares, value $6,230,727
- · All holdings are listed with sole voting and dispositive power
03-08-2026
EVP, CT & Ops Off, GM Foundry Chandrasekaran Nagasubramaniyan had withheld for taxes 14,738 Common Stock at $90.04 (~$1.33M). Chandrasekaran Nagasubramaniyan holds 224,121 shares after the transaction.
- · EVP, CT & Ops Off, GM Foundry Chandrasekaran Nagasubramaniyan exercised/converted 33,007 Common Stock
- · EVP, CT & Ops Off, GM Foundry Chandrasekaran Nagasubramaniyan had withheld for taxes 14,738 Common Stock at $90.04 (~$1.33M)
- · EVP, CT & Ops Off, GM Foundry Chandrasekaran Nagasubramaniyan exercised/converted 33,007 Restricted Stock Units
03-08-2026
Strategy Inc (STRD) disclosed weekly ATM sales, bitcoin holdings, and share repurchase activity for the period July 27 to August 2, 2026. The company sold 3,011,361 shares of Class A common stock (MSTR) for net proceeds of $290.6 million, while no preferred stock was sold under the ATM. Bitcoin holdings decreased by 1,638 BTC (sold at an average price of $63,957) to 842,138 BTC, with proceeds used to fund preferred dividends and STRC repurchases. The USD Reserve stood at $4.0 billion, and the dividend rate on STRC stock was maintained at 12.00% per annum.
- · No preferred stock (STRF, STRC, STRK, STRD) was sold under the ATM during the period.
- · Of the $290.6M MSTR proceeds, $250.0M was added to the USD Reserve, $28.9M used for STRC repurchases, and $11.7M added to cash balance.
- · Bitcoin sales of 1,638 BTC generated $104.73M; $52.4M funded preferred dividends and $52.3M funded STRC repurchases.
- · Average bitcoin purchase price across all holdings is $75,419 per BTC.
- · Dividends on STRC stock for semi-monthly periods ending Aug 31 and Sep 15, 2026 are $0.50 per share (12.00% annual rate).
- · Dividends are expected to be characterized as non-taxable returns of capital for U.S. federal income tax purposes.
- · The MSTR ATM capacity includes a $21.0 billion increase announced March 23, 2026; sales under the increase may begin once existing capacity is substantially depleted.
Get daily alerts with 8 investment signals, 8 risk alerts, 6 opportunities and full AI analysis of all 8 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Nasdaq 100 Stocks SEC Filings
🇺🇸 More from United States
View all →August 03, 2026
US Pre-Market SEC Filings Roundup — August 03, 2026
US Pre-Market SEC Filings Roundup
August 03, 2026
US Activist Hedge Fund Institutional SEC 13D 13G — August 03, 2026
US Activist Hedge Fund Institutional SEC 13D 13G
August 03, 2026
S&P 500 Financials Sector SEC Filings — August 03, 2026
S&P 500 Financials Sector SEC Filings
August 03, 2026
S&P 500 Consumer Staples Sector SEC Filings — August 03, 2026
S&P 500 Consumer Staples Sector SEC Filings